Table 1.
Summary of CSF1R targeted therapies for leukemias in clinical trials (2020).
| Compound | Class | Target | Clinical phase | Status | ClinicalTrials.gov identifier | Sponsor |
|---|---|---|---|---|---|---|
| Pexidartinib (PLX3397/PLX10801) | Small molecule | CSF1R, FLT3, cKIT | I/II | Completed [44] | NCT01349049 | Daiichi Sankyo, Inc. |
| I/II | Ongoing | NCT02390752 | National Cancer Institute (NCI) | |||
| JNJ-40346527 | Small molecule | CSF1R | II | Terminated | NCT03557970 | OHSU Knight Cancer Institute |
| NMS-03592088 | Small molecule | CSF1R, FLT3, cKIT | I/II | Ongoing | NCT03922100 | Nerviano Medical Sciences |
| Emactuzumab (RG7155) | mAb | CSF1R | I | Ongoing | NCT02323191 | Hoffmann-La Roche |